AYSEGUL A. SAHIN, M.D.
Medical Practice at Holcombe Blvd, Houston, TX
License number
Texas H5049
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about AYSEGUL A. SAHIN at radaris.comName
Address
Phone
3803 University Blvd, Houston, TX 77005
7320 Staffordshire St, Houston, TX 77030
3027 Russett Pl W, Pearland, TX 77584
7575 Cambridge St, Houston, TX 77054
2300 Old Spanish Trl, Houston, TX 77054
Professional information
Professor At Md Anderson Cancer Center
Position:
Professor at MD Anderson Cancer Center
Location:
Houston, Texas Area
Industry:
Medical Practice
Work:
MD Anderson Cancer Center
-
Professor
Education:
University of Ankara
Doctor of Medicine (MD)
Doctor of Medicine (MD)
Skills:
Cancer Research, Breast Cancer, Breast Pathology
Aysegul Atsuren Sahin, Houston TX
Specialties:
Pathology, Anatomic Pathology & Clinical Pathology, Anatomic Pathology
Work:
Univ. of Texas M.D. Anderson C.
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
Ankara Universitesi (1980)
Diagnostic And Therapeutic Methods And Compositions Involving Pten And Breast Cancer
US Patent:
2012003, Feb 16, 2012
Filed:
Jul 15, 2011
Appl. No.:
13/184269
Inventors:
Dihua Yu - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco J. Esteva - Bellaire TX, US
Aysegul A. Sahin - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco J. Esteva - Bellaire TX, US
Aysegul A. Sahin - Houston TX, US
Assignee:
Board of Regents of The University of Texas System - Austin TX
International Classification:
A61K 39/395, A61P 35/00, C12Q 1/68
US Classification:
4241331, 435 611
Abstract:
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
Diagnostic And Therapeutic Methods And Compositions Involving Pten And Breast Cancer
US Patent:
2011015, Jun 23, 2011
Filed:
Nov 10, 2010
Appl. No.:
12/943644
Inventors:
Dihua Yu - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco J. Esteva - Bellaire TX, US
Aysegul A. Sahin - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco J. Esteva - Bellaire TX, US
Aysegul A. Sahin - Houston TX, US
Assignee:
Board of Regents of The University of Texas System - Austin TX
International Classification:
A61K 39/395, A61P 35/00, C12Q 1/68, G01N 33/573, C12Q 1/42
US Classification:
4241331, 435 611, 435 613, 435 723, 435 21
Abstract:
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
Compositions, Kits, And Methods For Identification, Assessment, Prevention, And Therapy Of Breast Cancer
US Patent:
2008031, Dec 18, 2008
Filed:
Jun 25, 2007
Appl. No.:
11/821773
Inventors:
James Lillie - Weston MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John E. Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel E. Meyers - Newton MA, US
Gabriel N. Hortobagyi - Bellaire TX, US
Lajos Pusztai - Houston TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon B. Mills - Houston TX, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John E. Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel E. Meyers - Newton MA, US
Gabriel N. Hortobagyi - Bellaire TX, US
Lajos Pusztai - Houston TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon B. Mills - Houston TX, US
Assignee:
MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
Board of Regents, The University of Texas System - Austin TX
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435 6, 435 723
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
Diagnostic And Therapeutic Methods And Compositions Involving Pten And Breast Cancer
US Patent:
2005028, Dec 29, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/983011
Inventors:
Dihua Yu - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco Esteva - Bellaire TX, US
Aysegul Sahin - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco Esteva - Bellaire TX, US
Aysegul Sahin - Houston TX, US
International Classification:
C12Q001/68, G01N033/574
US Classification:
435006000, 435007230
Abstract:
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
Dr. Aysegul A Sahin, Houston TX - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology, Pathology
Address:
1515 Holcombe Blvd SUITE 85, Houston 77030
(713) 792-6161 (Phone)
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
(713) 792-6161 (Phone)
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
Certifications:
Anatomic & Clinical Pathology, 1987, Pathology Recertification, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1515 Holcombe Blvd SUITE 85, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical School
Ankara University / Medical Faculty
Oregon Health and Science University
University Of Iowa Hospitals & Clinics
Ankara University / Medical Faculty
Oregon Health and Science University
University Of Iowa Hospitals & Clinics
Compositions, Kits, And Methods For Identification, Assessment, Prevention, And Therapy Of Breast Cancer
US Patent:
2003012, Jul 3, 2003
Filed:
Jun 21, 2002
Appl. No.:
10/177293
Inventors:
James Lillie - Natick MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel Meyers - Newton MA, US
Robert Bast - Houston TX, US
Gabriel Hortobagyi - Bellaire TX, US
Lajos Pusztai - Pearland TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon Mills - Houston TX, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel Meyers - Newton MA, US
Robert Bast - Houston TX, US
Gabriel Hortobagyi - Bellaire TX, US
Lajos Pusztai - Pearland TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon Mills - Houston TX, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K039/395, C12Q001/68, G01N033/574, C07H021/04, C12N009/00, C12P021/02, C12N005/06
US Classification:
424/155100, 435/006000, 435/069100, 435/183000, 435/320100, 435/325000, 530/388800, 536/023200, 435/007230
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.